about
Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activityActivation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmanninThe NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor geneCluster analysis of an extensive human breast cancer cell line protein expression map databaseInformed consent in randomised controlled trials: development and preliminary evaluation of a measure of Participatory and Informed Consent (PIC).PI3-kinase inhibition: a target for drug development?Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.The application of 2D gel-based proteomics methods to the study of breast cancer.Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer.Three-dimensional in vitro tissue culture models of breast cancer-- a review.OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee studyConveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians' Practices across Six Randomised Controlled Trials.Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis.Predictors of ovarian reserve in young women with breast cancerLactic acidosis. A presentation of metastatic breast cancer arising in pregnancy.Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches.Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial.Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation.Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right.Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.Structural and functional diversity of phosphoinositide 3-kinases.Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulinA double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours.An adaptive biomarker strategy clinical trial design.Efficient design of a phase III trial of competing tests for personalised cancer treatment in the absence of gold standard outcome data: challenges and potential solutions.Using adaptive designs for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests.Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework.Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice.Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment.IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patientsAbstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer
P50
Q22008497-82C68FD3-2755-4FD1-B68B-267C62DFC929Q24337678-B5E5E260-563C-448A-8D1E-A99D5E10672DQ24530221-EE66EF47-5A11-48AD-9B13-9F90C80BCEBDQ24645371-86738656-F882-4428-B353-B4ABD652ECEAQ28200792-336C56FA-09FA-4076-B898-EFB36B2D6D52Q33909403-7440CA52-4BEC-424B-BEE8-1FCF05479FDBQ34011982-CE3FCB37-051C-432A-A081-750F90513A2BQ34237829-1A613C76-BB54-422B-BF25-407538161BF9Q35185700-85F306FB-E3B0-47CA-88A2-E48FFC37A6B9Q35351175-5E1B1AAD-339C-4045-A855-E6DEED9CE8A0Q35551034-9906929A-F5BE-4258-8190-EF8F5F374809Q35757595-2DF32B46-649F-4250-9765-BC9412F47923Q35920893-905FDF47-94A3-4938-A5FA-E929E1B1132AQ35977532-41B0EE64-1FA2-48B1-9E07-C270CF15DA2BQ35981304-809D4DC2-8143-4E03-9DCD-47B45DECEB3BQ36166127-A261C716-AE6E-43CD-BE97-49A29EB10803Q36188568-6EA0EF42-EFFE-422B-A190-F33552395A40Q36609671-5A403A3D-624C-495B-99EB-C3A874BA869FQ36729506-4BE916F4-809A-41C5-BF09-178B1215CDC3Q37533025-93308D76-A68C-4110-8372-65F6DCCCEF2CQ37711677-422AC72F-E36F-4B11-AF78-736117BA36C2Q38069849-69A1967A-66C6-4874-A366-53EF7DE929B2Q38317182-D7090EAA-57EE-4AE3-B830-1A49397126DBQ38950160-3CF331CD-997C-4DBB-AFFC-F9B22E620099Q39831978-DAFA961F-F25B-4ED3-8578-057B878D257EQ39884856-58E99200-B71C-4BD7-B65F-F0CADC82D1F7Q40149301-3119805D-641D-4C16-AFF1-C312CAD2B8BFQ40998279-17F40F38-FA85-4DBE-81A7-606FFF06484EQ41818985-E978A2EA-C84C-4107-BDE4-99F6E3D1DAABQ44058854-7CE3F350-9CF1-4DB5-A406-C8494FEF0EC1Q46407781-C3235B1F-7AAD-46D1-9DFF-595D47D58F37Q46408175-E3E60645-A207-4A8F-9137-47DA976B0EEFQ46428117-95E11E0D-C853-41F3-A48A-76022C9B6729Q47556957-446A591B-689C-4A74-AFE1-0D49665862A0Q52804928-067CEFA7-9807-402F-A151-BF9ADFCF5249Q52841019-166F9CE4-1F6D-405D-9DCD-81CE6FB32FB9Q53111208-C316B771-06F8-4E71-9AB8-928A775212B1Q55395025-F37EC660-E694-4C00-A9B2-F019A02F58DBQ58333416-51366A9F-5B5E-4CD0-9A3F-B8C66EE70266Q59391955-D6E84E93-9EF6-411B-A15F-D47DC9B9B10A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rob Stein
@ast
Rob Stein
@en
Rob Stein
@es
Rob Stein
@nl
type
label
Rob Stein
@ast
Rob Stein
@en
Rob Stein
@es
Rob Stein
@nl
prefLabel
Rob Stein
@ast
Rob Stein
@en
Rob Stein
@es
Rob Stein
@nl
P106
P1153
7402952709
P31
P496
0000-0003-2969-0415